Subjective Effects, Misuse, and Adverse Effects of Osmotic-Release Methylphenidate Treatment in Adolescent Substance Abusers with Attention-Deficit/Hyperactivity Disorder
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Psychostimulants are effective treatments for attention-deficit/hyperactivity disorder (ADHD) but may be associated with euphoric effects, misuse/diversion, and adverse effects. These risks are perceived by some clinicians to be greater in substance-abusing adolescents relative to non-substance-abusing adults. The present study evaluates the subjective effects, misuse/diversion, and adverse effects associated with the use of osmotic-release oral system methylphenidate (OROS-MPH), relative to placebo, for treating ADHD in adolescents with a substance use disorder (SUD) as a function of substance use severity and compared these risks with those associated with the treatment of ADHD in adults without a non-nicotine SUD. METHOD: Datasets from two randomized placebo-controlled trials of OROS-MPH for treating ADHD, one conducted with 303 adolescents (13-18) with at least one non-nicotine SUD and one with 255 adult smokers (18-55), were analyzed. Outcome measures included the Massachusetts General Hospital Liking Scale, self-reported medication compliance, pill counts, and adverse events (AEs). RESULTS: Euphoric effects and misuse/diversion of OROS-MPH were not significantly affected by substance use severity. The euphoric effects of OROS-MPH did not significantly differ between the adolescent and adult samples. Adults rated OROS-MPH as more effective in treating ADHD, whereas adolescents reported feeling more depressed when taking OROS-MPH. The adolescents lost more pills relative to the adults regardless of treatment condition, which suggests the importance of careful medication monitoring. Higher baseline use of alcohol and cannabis was associated with an increased risk of experiencing a treatment-related AE in OROS-MPH, but baseline use did not increase the risk of serious AEs or of any particular category of AE and the adolescents did not experience more treatment-related AEs relative to the adults. CONCLUSIONS: With good monitoring, and in the context of substance abuse treatment, OROS-MPH can be safely used in adolescents with an SUD despite non-abstinence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sobell, L. C., & Sobell, M. B. (1992) · Measuring Alcohol Consumption · doi:10.1007/978-1-4612-0357-5_3 · Cited by 4,110
Kessler, R. C., Adler, L., Barkley, R., Biederman, J., Conners, C. K., Demler, O., Faraone, S. V., Greenhill, L. L., Howes, M. J., Secnik, K., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.716 · Cited by 3,886
Self-citationMisuse and Diversion of Stimulants Prescribed for ADHD: A Systematic Review of the Literature
WILENS, T. E., ADLER, L. A., ADAMS, J., SGAMBATI, S., ROTROSEN, J., SAWTELLE, R., UTZINGER, L., & FUSILLO, S. (2008) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e31815a56f1 · Cited by 824 · cited 1×
“Research suggests that misuse/diversion of psychostimulants by adolescents and young adults is less for long-acting, relative to IR, formulations (Wilens et al. 2008).”
BackgroundSelf-citationAttention-Deficit/Hyperactivity Disorder: Diagnosis, Lifespan, Comorbidities, and Neurobiology
Spencer, T. J., Biederman, J., & Mick, E. (2007) · Journal of Pediatric Psychology · doi:10.1093/jpepsy/jsm005 · Cited by 634 · cited 2×
“2006), is characterized by symptoms of inattention, impulsivity, and hyperactivity and is associated with significant impairment in functioning, including poorer performance in educational and occupational settings and higher rates of other psychiatric disorders (Spencer et al. 2007).”
BackgroundGREENHILL, L. L., HALPERIN, J. M., & ABIKOFF, H. (1999) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199905000-00011 · Cited by 268
Kollins, S. H. (2008) · Journal of Attention Disorders · doi:10.1177/1087054707311654 · Cited by 136
Kollins, S. H., English, J., Robinson, R., Hallyburton, M., & Chrisman, A. K. (2009) · Psychopharmacology · doi:10.1007/s00213-008-1439-6 · Cited by 48 · cited 3×
“Previous research has found that the likeability of psychostimulants in individuals with ADHD is associated more with therapeutic effect than with euphoric effects (Fredericks and Kollins 2004 2005; Kollins et al. 2009).”
BackgroundMethod
Cited by
Medication for Attention Deficit–Hyperactivity Disorder and Criminality
Lichtenstein, P., Halldner, L., Zetterqvist, J., Sjölander, A., Serlachius, E., Fazel, S., Långström, N., & Larsson, H. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203241 · Cited by 611
Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Storebø, O. J., Ramstad, E., Krogh, H. B., Nilausen, T. D., Skoog, M., Holmskov, M., Rosendal, S., Groth, C., Magnusson, F. L., Moreira-Maia, C. R., et al. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009885.pub2 · Cited by 347
Stimulant ADHD medication and risk for substance abuse
Chang, Z., Lichtenstein, P., Halldner, L., D'Onofrio, B., Serlachius, E., Fazel, S., Långström, N., & Larsson, H. (2014) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12164 · Cited by 225
“Among these, there have been concerns over the long-term effects on the development of substance abuse (Humphreys, Eng, & Lee, 2013; Singh, 2008; Winhusen et al., 2011), where researchers and clinicians have proposed that risk for substance abuse might be particularly pronounced for youths who use…”
InfluentialZulauf, C. A., Sprich, S. E., Safren, S. A., & Wilens, T. E. (2014) · Current Psychiatry Reports · doi:10.1007/s11920-013-0436-6 · Cited by 214
Levin, F. R., Mariani, J. J., Specker, S., Mooney, M., Mahony, A., Brooks, D. J., Babb, D., Bai, Y., Eberly, L. E., Nunes, E. V., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.41 · Cited by 179
Levin, F. R., Mariani, J. J., Pavlicova, M., Choi, C. J., Mahony, A. L., Brooks, D. J., Bisaga, A., Dakwar, E., Carpenter, K. M., Naqvi, N., et al. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.107700 · Cited by 54
“Supporting this, a prior trial evaluating long-acting methylphenidate for adolescents with attentiondeficit hyperactivity disorder and substance use disorders, loss of pills (and possible diversion) was no different in the methyphenidate or placebo arms ( Winhusen et al. 2011).”
BackgroundTamm, L., Trello-Rishel, K., Riggs, P., Nakonezny, P. A., Acosta, M., Bailey, G., & Winhusen, T. (2013) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2012.07.001 · Cited by 52
“…is partly due to the fact that individuals with comorbid SUD are often excluded from ADHD pharmacotherapy trials due to concerns about potential adverse interactions between medication and drugs/alcohol and concern about potential use and diversion (Whitmore & Riggs, 2006; Winhusen et al., 2011).”
BackgroundInfluentialSelf-citationWilens, T., Zulauf, C., Martelon, M., Morrison, N. R., Simon, A., Carrellas, N. W., Yule, A., & Anselmo, R. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09559 · Cited by 35
Treatments for Adolescents With Comorbid ADHD and Substance Use Disorder: A Systematic Review
Zaso, M. J., Park, A., & Antshel, K. M. (2020) · Journal of Attention Disorders · doi:10.1177/1087054715569280 · Cited by 31
Metadata
- Authors
- Winhusen, T. M., Lewis, D. F., Riggs, P. D., Davies, R. D., Adler, L. A., Sonne, S., & Somoza, E. C.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2011-10
- Volume
- 21
- Issue
- 5
- Pages
- 455-463
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- OpenAlex
- W2086784339
- Cited by
- 53
- References
- 7
- FWCI
- 2.95
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.